Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick

    Editors Pick - Page 34

    Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

    Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

    Meghna A Singhania17 April 2019 12:26 PM IST
    New Delhi: The national regulatory body for Indian Pharmaceutical and Medical Device, Central Drugs Standard Control Organisation (CDSCO) has ordered...
    Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

    Alchem solves stability dilemma for micronized DIGOXIN; files PATENT for novel production process

    Meghna A Singhania16 April 2019 4:47 PM IST
    Alchem's molecule is the sole micronized digoxin available globally that resolves the challenge of micro dosage formulation and the long-term...
    CDSCO expert committee suggests ban of yet another 324 FDCs

    CDSCO expert committee suggests ban of yet another 324 FDCs

    Meghna A Singhania15 April 2019 11:49 AM IST
    New Delhi: Domestic drugmakers are likely to face a blow as 324 Fixed Dose Combination (FDCs) drugs have been recommended to be banned by an expert...
    MMC develops potential TB drugs; awaits permission from CDSCO for mass manufacture

    MMC develops potential TB drugs; awaits permission from CDSCO for mass manufacture

    Meghna A Singhania14 April 2019 4:00 PM IST
    Chennai: In a major breakthrough, the Madras Medical College (MMC) has developed not just one but two anti-tuberculosis drug formulations. According...
    Upload application in SUGAM as per new Rules: CDSCO issues notice

    Upload application in SUGAM as per new Rules: CDSCO issues notice

    Meghna A Singhania13 April 2019 1:39 PM IST
    New Delhi: Through a recent notice, the Central Drugs Standard Control Organization (CDSCO) has informed that uploading of applications through SUGAM...
    Insider trading: Sun Pharma Senior Executive, wife pay over Rs 70 lakh settlement to SEBI

    Insider trading: Sun Pharma Senior Executive, wife pay over Rs 70 lakh settlement to SEBI

    Meghna A Singhania12 April 2019 10:59 AM IST
    Abhay Arvind Gandhi and his wife traded in Ranbaxy shares soon after Japanese major Daiichi, in 2014, agreed to sell Ranbaxy to Sun Pharma. New Delhi:...
    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Intas Pharma launches Cancer Drug Eleftha for Rs 19,995; 65 percent lower than market rate

    Meghna A Singhania11 April 2019 10:50 AM IST
    Mumbai: In a move that will provide relief to cancer patients, drugmaker Intas Pharmaceuticals has recently announced the launch of Trastuzumab...
    Niramai to target River Blindness; plans to develop AI based software

    Niramai to target River Blindness; plans to develop AI based software

    Garima10 April 2019 9:57 AM IST
    Niramai has developed a novel technique called Thermalytix, an automated diagnostic tool, which combines thermal imaging with artificial intelligence...
    Panacea Biotec Bail out: Piramal, Bain offer Rs 992 crore deal

    Panacea Biotec Bail out: Piramal, Bain offer Rs 992 crore deal

    Garima9 April 2019 9:45 AM IST
    MUMBAI: India Resurgence Fund (IRF) led by Piramal Enterprises and Bain Capital Credit recently said it will invest Rs 992 crore in New Delhi-based...
    51 percent Controlling stake in Pune based Sahyadri Hospitals bought by Everstone

    51 percent Controlling stake in Pune based Sahyadri Hospitals bought by Everstone

    Garima8 April 2019 10:02 AM IST
    Mumbai: India and South-East Asia focused investment group, Everstone has agreed to buy a controlling stake in Sahyadri Hospitals Ltd(SHL). According...
    Government to ban export of anti-rabies vaccine; Bharat Biotech biz likely to take hit : Report

    Government to ban export of anti-rabies vaccine; Bharat Biotech biz likely to take hit : Report

    Meghna A Singhania7 April 2019 11:00 AM IST
    New Delhi: Hyderabad based biotechnology firm, Bharat Biotech is likely to face setback as the Government plans to impose a ban on export of...
    Moopen backed Aster DM to infuse about Rs 1000 crore in Indian Hospitals by 2021: Report

    Moopen backed Aster DM to infuse about Rs 1000 crore in Indian Hospitals by 2021: Report

    Garima6 April 2019 11:30 AM IST
    Kochi: In a move to cater to healthcare facilities, Aster DM Healthcare is planning to infuse about Rs 1000 crore in India by 2021. According to...
    PrevNext

    Popular Stories

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Hydroxychloroquine not approved as anti-malarial drug in India, says Ipca Laboratories Joint MD

    Jubilant Life Sciences Q3 profit falls 23.97pc at Rs 203.38 crore

    Jubilant Life Sciences Q3 profit falls 23.97pc at Rs 203.38 crore

    Indian Genetics startup MedGenome raises Rs 415 crore in funding led by LeapFrog Investments

    Indian Genetics startup MedGenome raises Rs 415 crore in funding led by LeapFrog Investments

    NPPA fixes prices of 29 formulations under DPCO, check out details

    NPPA fixes prices of 29 formulations under DPCO, check out details

    Lupin gets USFDA EIR for Nagpur Facility

    Lupin gets USFDA EIR for Nagpur Facility

    Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

    Aurobindo Pharma gets USFDA nod for Fluoxetine Tablets

    SMS Pharma updates against USFDA statement on Ranitidine

    SMS Pharma updates against USFDA statement on Ranitidine

    KKRs Envision Healthcare hires bank to explore debt restructuring: Report

    KKR's Envision Healthcare hires bank to explore debt restructuring: Report

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok